## Somatostatin-Mediated Inhibition of Acid Secretion ### Dual Mechanism of Action **Key Point:** Somatostatin inhibits acid secretion through **two complementary pathways**: 1. **Paracrine inhibition** of histamine release from ECL cells 2. **Direct inhibition** of parietal cell secretion ### Mechanism at the Cellular Level Somatostatin binds to **somatostatin receptors (SSTR2 and SSTR4)** on: - **ECL cells:** Suppresses histamine synthesis and release - **Parietal cells:** Directly inhibits acid secretion via Gi-coupled pathways - **G cells:** Inhibits gastrin release (minor contribution) The receptor activation leads to: - Decreased intracellular cAMP - Reduced protein kinase A activity - Inhibition of H^+^/K^+^-ATPase activation ### Regulation of Somatostatin Secretion | Stimulus | Effect on D Cells | |----------|-------------------| | Low pH (< 3.0) | ↑↑ Somatostatin release | | Fatty acids | ↑ Somatostatin release | | Amino acids | ↑ Somatostatin release | | Gastrin | ↓ Somatostatin (disinhibition) | | Acetylcholine | ↓ Somatostatin (disinhibition) | **High-Yield:** Somatostatin is the **primary physiologic brake** on gastric acid secretion. Low pH directly stimulates D cells to release somatostatin, creating a negative feedback loop that prevents excessive acid production. **Clinical Pearl:** Octreotide (somatostatin analog) is used to control acid hypersecretion in Zollinger-Ellison syndrome by suppressing both gastrin-stimulated and basal acid secretion. **Mnemonic:** **SOMA** = Somatostatin Opposes Multiple Acid pathways (ECL cells + Parietal cells + G cells) ### Why Somatostatin Is Critical Somatostatin acts as a **paracrine and endocrine inhibitor**, making it the most important physiologic counterbalance to gastrin and histamine. Its action is not receptor antagonism but rather suppression of the upstream mediators and direct parietal cell inhibition.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.